1989
Symptomatic and asymptomatic 1 -methyl-4-phenyl-1,2,3,6-tetrahydropyridinetreated primates: Biochemical changes in striatal regions
Elsworth J, Deutch A, Redmond D, Taylor J, Sladek J, Roth R. Symptomatic and asymptomatic 1 -methyl-4-phenyl-1,2,3,6-tetrahydropyridinetreated primates: Biochemical changes in striatal regions. Neuroscience 1989, 33: 323-331. PMID: 2622529, DOI: 10.1016/0306-4522(89)90212-1.Peer-Reviewed Original ResearchConceptsHomovanillic acid concentrationsParkinson's diseaseStriatal regionsHomovanillic acid/dopamine ratioGross motor abnormalitiesDepletion of dopamineHomovanillic acid levelsLoss of dopamineIdiopathic Parkinson's diseaseCaudate nucleus dopamineAsymptomatic monkeysTetrahydropyridine (MPTP) treatmentAsymptomatic groupSymptomatic groupDopamine lossTetrahydropyridine (MPTP) toxicityMotor abnormalitiesDopamine ratioCaudate nucleusSignificant negative correlationVentromedial regionStriatum
1987
Differential responsiveness to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine toxicity in sub-regions of the primate substantia nigra and striatum
Elsworth J, Deutch A, Redmond D, Sladek J, Roth R. Differential responsiveness to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine toxicity in sub-regions of the primate substantia nigra and striatum. Life Sciences 1987, 40: 193-202. PMID: 3491946, DOI: 10.1016/0024-3205(87)90359-6.Peer-Reviewed Original ResearchConceptsSubstantia nigraParkinsonian disabilityDA neuronsSymptomatic animalsMedial regionAsymptomatic animalsHVA/DA ratioLateral regionsDA concentrationPrimate substantia nigraDA histofluorescenceNigrostriatal pathwayTetrahydropyridine (MPTP) toxicityDopaminergic neuronsContralateral halfDA ratioDopaminergic cellsLipofuscin fluorescenceCell bodiesStriatumIndividual neuronsNeuronsDifferential responsivenessMarked lossDopamine